CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.
The CSL Research Acceleration Initiative supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.
Successful applicants can receive up to $400,000 USD in non-dilutive funding over 2 years to advance their innovative programs.
Interested researchers are invited to:
•
Attend an information webinar (choose one of twosessions)
Tuesday, 20 January 4:00PM CET (UTC+1) –